Drug Discovery & Development - October 26, 2010
Rockland Immunochemicals Inc., a biotechnology company focusing on antibodies and antibody based tools for basic research, diagnostic assay development and preclinical studies, announced that it has received a Phase 1 Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Antibody therapy offers treatment for a wide range of diseases, and can extend the life of cancer patients, but the treatment cost is extremely expensive. As patent protection of some current antibodies expires in coming years, there is an opportunity to develop generic and lower priced versions of these therapeutic biologics for the treatment of cancer. To accelerate the development of a generic version of the popular anti-cancer drugs Herceptin, Rituxan, Zevalin and Erbitux, Rockland will construct vectors of these antibodies.
The biologics developed by Rockland will be effective for antibody therapy. Available as lower priced generic versions of current anti-cancer antibodies, these therapeutics will make the treatment of the disease more affordable and accessible for all cancer patients.
In September of this year, Rockland announced the receipt of an SBIR grant to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway. That grant will support the development of an Akt assay to monitor Akt activation, measuring total Akt as well as levels of both major forms of phosphorylated Akt at THR308 or SER473, and allow for the calculation of minimal drug inhibiting concentration (IC50) for cancer cells in the presence of mTOR/Akt pathway inhibitors.
Date: October 26, 2010
Source: Rockland Immunochemicals Inc.
Antibody therapy offers treatment for a wide range of diseases, and can extend the life of cancer patients, but the treatment cost is extremely expensive. As patent protection of some current antibodies expires in coming years, there is an opportunity to develop generic and lower priced versions of these therapeutic biologics for the treatment of cancer. To accelerate the development of a generic version of the popular anti-cancer drugs Herceptin, Rituxan, Zevalin and Erbitux, Rockland will construct vectors of these antibodies.
The biologics developed by Rockland will be effective for antibody therapy. Available as lower priced generic versions of current anti-cancer antibodies, these therapeutics will make the treatment of the disease more affordable and accessible for all cancer patients.
In September of this year, Rockland announced the receipt of an SBIR grant to develop a pharmacodynamic assay to monitor the Akt/mTOR signaling pathway. That grant will support the development of an Akt assay to monitor Akt activation, measuring total Akt as well as levels of both major forms of phosphorylated Akt at THR308 or SER473, and allow for the calculation of minimal drug inhibiting concentration (IC50) for cancer cells in the presence of mTOR/Akt pathway inhibitors.
Date: October 26, 2010
Source: Rockland Immunochemicals Inc.
No hay comentarios:
Publicar un comentario